Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib with Oxaliplatin and Radiotherapy for Esophageal Carcinoma
NCT00093652Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- May 2003
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in esophageal cancer, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose and Objective Response Rate. Started May 2003; status: terminated.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00093652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093652.